Neoadjuvant

Phase III ALINA study shows Alecensa’s superior disease-free survival benefit in early-stage lung cancer patients

ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...